三阴性乳腺癌治疗进展附视频

被引：40

作者：

张继博

史业辉

贾勇圣

佟仲生

机构：

[1] 天津医科大学肿瘤医院乳腺肿瘤内科国家肿瘤临床研究中心天津市“肿瘤防治”重点实验室天津市恶性肿瘤临床医学研究中心

来源：

肿瘤 | 2017年 / 07期

关键词：

乳腺肿瘤; 三阴性乳腺癌; 新辅助化疗; 辅助化疗; 靶向治疗; 免疫治疗;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

乳腺癌是全世界最常见的一种女性恶性肿瘤。三阴性乳腺癌是指雌激素受体、孕激素受体和人表皮生长因子受体2的表达均为阴性的乳腺癌,约占所有乳腺癌病理类型的15%20%。三阴性乳腺癌的预后差、复发转移率高、死亡率高,已成为近年来乳腺癌研究和关注的焦点。目前针对乳腺癌的治疗手段包括手术治疗、新辅助化疗、辅助化疗、内分泌治疗和靶向治疗等。由于三阴性乳腺癌患者缺少雌激素受体、孕激素受体和人表皮生长因子受体2的表达,因此患者无法从针对乳腺癌的内分泌治疗及抗人表皮生长因子受体2的靶向治疗中获益。化疗是目前较推荐的三阴性乳腺癌治疗方法。许多化疗方案及新型的化疗药物也正在探索之中。本文对三阴性乳腺癌的化疗、内分泌治疗、靶向治疗和免疫治疗的研究进展进行综述。

引用

页码：788 / 794

页数：7

共 14 条

[1] Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer [J].

Nabholtz, J. M. ;

Chalabi, N. ;

Radosevic-Robin, N. ;

Dauplat, M. M. ;

Mouret-Reynier, M. A. ;

Van Praagh, I. ;

Servent, V. ;

Jacquin, J. P. ;

Benmammar, K. E. ;

Kullab, S. ;

Bahadoor, M. R. K. ;

Kwiatkowski, F. ;

Cayre, A. ;

Abrial, C. ;

Durando, X. ;

Bignon, Y. J. ;

Chollet, P. ;

Penault-Llorca, F. .

INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (09) :2274-2280

[2] A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes [J].

Li, Qiao ;

Li, Qing ;

Zhang, Pin ;

Yuan, Peng ;

Wang, Jiayu ;

Ma, Fei ;

Luo, Yang ;

Fan, Ying ;

Cai, Ruigang ;

Xu, Binghe .

CANCER BIOLOGY & THERAPY, 2015, 16 (12) :1746-1753

[3]

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40[NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial[J] . Harry D Bear,Gong Tang,Priya Rastogi,Charles E Geyer,Qing Liu,André Robidoux,Luis Baez-Diaz,Adam M Brufsky,Rita S Mehta,Louis Fehrenbacher,James A Young,Francis M Senecal,Rakesh Gaur,Richard G Margolese,Paul T Adams,Howard M Gross,Joseph P Costantino,Soonmyung Paik,Sandra M Swain,Eleftherios P Mamounas,Norman Wolmark.The Lancet Oncology . 2015

[4] The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells [J].

Arun, Banu ;

Akar, Ugur ;

Gutierrez-Barrera, Angelica M. ;

Hortobagyi, Gabriel N. ;

Ozpolat, Bulent .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) :262-268

[5]

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies[J] . Chris Twelves,Javier Cortes,Linda Vahdat,Martin Olivo,Yi He,Peter A. Kaufman,Ahmad Awada.Breast Cancer Research and Treatment . 2014 (3)

[6]

Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer[J] . H.A. Alagizy,M.A. Shehata,T.A. Hashem,K.K. Abdelaziz,M.M. Swiha.Hematology/Oncology and Stem Cell Therapy . 2014

[7]

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66): a randomised phase 2 trial[J] . Gunter von Minckwitz,Andreas Schneeweiss,Sibylle Loibl,Christoph Salat,Carsten Denkert,Mahdi Rezai,Jens U Blohmer,Christian Jackisch,Stefan Paepke,Bernd Gerber,Dirk M Zahm,Sherko Kümmel,Holger Eidtmann,Peter Klare,Jens Huober,Serban Costa,Hans Tesch,Claus Hanusch,J?rn Hilfrich,Fariba Khandan,Peter A Fasching,Bruno V Sinn,Knut Engels,Keyur Mehta,Valen

[8]

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer[J] . Ayca Gucalp,Sara Tolaney,Steven J. Isakoff,James N. Ingle,Minetta C. Liu,Lisa A. Carey,Kimberly Blackwell,Hope Rugo,Lisle Nabell,Andres Forero,Vered Stearns,Ashley S. Doane,Michael Danso,Mary Ellen Moynahan,Lamia F. Momen,Joseph M. Gonzalez,Arooj Akhtar,Dilip D. Giri,Sujata Patil,Kimberly N. Feigin,Clifford A. Hudis,Tiffany A. Traina.Clinical Cancer Research . 2013

[9] Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes [J].

Masuda, Hiroko ;

Baggerly, Keith A. ;

Wang, Ying ;

Zhang, Ya ;

Gonzalez-Angulo, Ana Maria ;

Meric-Bernstam, Funda ;

Valero, Vicente ;

Lehmann, Brian D. ;

Pietenpol, Jennifer A. ;

Hortobagyi, Gabriel N. ;

Symmans, W. Fraser ;

Ueno, Naoto T. .

CLINICAL CANCER RESEARCH, 2013, 19 (19) :5533-5540

[10]

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial[J] . David Cameron,Julia Brown,Rebecca Dent,Christian Jackisch,John Mackey,Xavier Pivot,Guenther G Steger,Thomas M Suter,Masakazu Toi,Mahesh Parmar,Rita Laeufle,Young-Hyuck Im,Gilles Romieu,Vernon Harvey,Oleg Lipatov,Tadeusz Pienkowski,Paul Cottu,Arlene Chan,Seock-Ah Im,Peter S Hall,Lida Bubuteishvili-Pacaud,Volkmar Henschel,Regula J Deurloo,Celine Pallaud,Richard B

← 1 2 →